Truqap plus Faslodex recommended for approval in the EU by C

AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been recommended for approval in the European Union (EU) for the treatment of adult patients with estrogen receptor (ER)-positive, HER2‑negative locally advanced or metastatic breast cancer with one or more PIK3CA, AKT1, or ...

Related Keywords

United Kingdom , Canada , Japan , Cambridge , Cambridgeshire , Astrazeneca Truqap , Daiichi Sankyo , Cancer Research Technology , Committee For Medicinal Products Human Use , World Health Organization , Investor Relations Team , National Comprehensive Cancer Network , Astrazeneca , European Medicines Agency , Institute Of Cancer Research , Merck Co Inc , European Union , Nasdaq , National Cancer Institute , End Results Program , Medicinal Products , Human Use , New England Journal , Astex Therapeutics , Cancer Research , Cancer Research Technology Limited , Rare Diseases , Hormone Receptor , Positive Advanced Breast , Accessed April , End Results , Receptor Negative , Progesterone Receptor Positive Breast Carcinomas , How Frequent , Genetic Alterations , Everolimus Benefit , Hormone Receptor Positive , Human Epidermal Growth Factor Receptor , Negative Advanced Breast Cancer , Results From , Overall Survival , Plus Endocrine Therapy , Therapy Alone , Advanced Hormone Receptor , Breast Cancer , Emerging Therapeutic , Clin Cancer , Comprehensive Cancer , Clinical Practice Guidelines ,